Home Cart Sign in  
Chemical Structure| 329689-23-8 Chemical Structure| 329689-23-8

Structure of Monastrol
CAS No.: 329689-23-8

Chemical Structure| 329689-23-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Monastrol is a specific and allosteric inhibitor of mitotic molecular motor kinesin Eg5 with IC50 value of 14 μM.

Synonyms: (±)-Monastrol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Monastrol

CAS No. :329689-23-8
Formula : C14H16N2O3S
M.W : 292.35
SMILES Code : O=C(C1=C(C)NC(NC1C2=CC=CC(O)=C2)=S)OCC
Synonyms :
(±)-Monastrol
MDL No. :MFCD00813077
InChI Key :LOBCDGHHHHGHFA-UHFFFAOYSA-N
Pubchem ID :2987927

Safety of Monastrol

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Monastrol

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293T cells 25µM and 100µM 4 h and 24 h Monastrol treatment resulted in a pronounced increase in Mcl-1S mRNA content, but no increase at the protein level. 25µM Monastrol only slightly increased the proportion of cells in G2/M phase, while 100µM Monastrol effectively arrested cells in G2/M phase. PMC7544834
Human induced pluripotent stem cells-derived secondary motor neurons 100 µmol and 10 µmol 48 h To evaluate the effect of Monastrol on the neurite outgrowth of secondary motor neurons, the results showed that Monastrol significantly and dose-dependently accelerated neurite outgrowth. PMC10257330
NOZ cells 15μM and 20μM 48 h Monastrol induced G2M phase cell cycle arrest and inhibited cell proliferation. PMC7893577
EH-GB1 cells 15μM and 20μM 48 h Monastrol induced G2M phase cell cycle arrest and inhibited cell proliferation. PMC7893577
U2OS cells 100μM 1 h or 6 h To investigate the effect of Monastrol treatment on cyclin A levels and k-MT attachment stability. Results showed that after 6 h of treatment, cyclin A levels decreased by 60%, and k-MT attachment stability significantly increased. PMC3791168
RPE-1 cells 15 μM 40 min Reduced the frequency of lagging chromosomes PMC3277651
CaCo-2 cells 15 μM 16 h Reduced the frequency of lagging chromosomes and spindle length PMC3277651
BS-C-1 cells 100 µM 4 h To test the effect of Monastrol on the cell cycle, it was found that Monastrol does not inhibit S phase, G2 phase, or mitotic entry, and the mitotic arrest it induces is reversible. PMC2175262
Ptk2 cells 50 µM 4 h To test the effect of Monastrol on centrosome separation, it was found that Monastrol does not inhibit centrosome duplication but inhibits centrosome separation. PMC2175262
Xenopus egg extracts 50 µM To test the effect of Monastrol on bipolar spindle formation in Xenopus egg extracts, it was found that Monastrol inhibits the formation of bipolar spindles. PMC2175262

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Lewis rats Experimental autoimmune neuritis (EAN) model Intraperitoneal injection 1 mg/kg Injected on day 18, day 22, and day 26 To evaluate the effect of Monastrol on functional and histological recovery in the EAN model, the results showed that Monastrol significantly enhanced functional and histological recovery and accelerated the recovery of motor nerve conduction velocity. PMC10257330

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.42mL

0.68mL

0.34mL

17.10mL

3.42mL

1.71mL

34.21mL

6.84mL

3.42mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories